AIM AIM ImmunoTech

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications

Company to host conference call and webcast today, May 16, at 8:30 AM ET

OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below).

“AIM is making fundamental progress across our clinical development programs and continues to be encouraged by Ampligen’s potential. We recently reported encouraging top-line data across our pipeline. We also recently completed cGMP manufacturing of 9,000 vials of Ampligen. Both of these successes are extremely important as we seek commercial partners. We remain focused on the continued execution of our operational, clinical and regulatory initiatives and seek to generate — through such progress — a basis for increased stockholder value,” commented AIM Chief Executive Officer Thomas K. Equels.

Recent Highlights

  • Completed cGMP manufacturing of clinical vials of Ampligen
  • in Phase 1b/2 study of Ampligen and Imfinzi as a combination therapy for late-stage pancreatic cancer
  • Announced appointment of Charles Lapp, MD as a Consulting Medical Officer for AIM’s ME/CFS and Long COVID programs
  • Reported from the study of Ampligen combined with pembrolizumab for the treatment of recurrent ovarian cancer:
    • In the ongoing, investigator-initiated Phase 2, single-arm efficacy/safety trial, University of Pittsburgh Medical Center researchers saw an Objective Response Rate of 45% when combining Ampligen, pembrolizumab and cisplatin in platinum-sensitive subjects with recurrent ovarian cancer. Objective Response Rate includes complete response and partial response to treatment. There was a total Clinical Benefit Rate of 55% when including patients who experienced stable disease. Researchers also reported a median Progression-Free Survival of 7.8 months.
  • Released multiple segments highlighting Company news and clinical programs

Expected Upcoming Pipeline Milestones

Q2 2024

  • Final dataset for Post-COVID Conditions (AMP-518)

2024

  • Locally Advanced Pancreatic Adenocarcinoma (AMP-270) – First Subject Dosed
  • Publications of data in scientific journals

Summary of Financial Highlights for First Quarter 2024

  • As of March 31, 2024, AIM reported cash, cash equivalents and marketable securities of $10.9 million.
  • Research and development expenses for the three months ended March 31, 2024, were $2.0 million, compared to $2.1 million for the same period in 2023.
  • General and administrative expenses were $3.8 million for the three months ended March 31, 2024, compared to $2.3 million for the same period 2023.
  • The net loss from operations for the three months March 31, 2024, was $5.8 million, or $0.12 per share, compared to $3.7 million, or $0.08 per share, for the three months ended March 31, 2023.

Please refer to the full 10-Q for complete details.

Conference Call and Webcast Details

As previously announced, the Company will host a to discuss the Company’s Q1 2024 operational and financial results today, May 16, 2024 at 8:30 AM ET.

The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The will be accessible on the page of the section of the Company’s website, , and will be archived for 90 days following the live event.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit  and connect with the Company on , , and .

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
 
EN
16/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference Live video webcast on Monday, June 17th at 1:00 PM ET OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that of AIM will participate in the on Monday, June 17, 2024 at 1:00 PM ET. As part of the event, Mr. Equels will provide an “elevator pitch” and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many que...

 PRESS RELEASE

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Seri...

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that of AIM will participate in the on Wednesday, June 5, 2024 at 12:00 PM ET. As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the...

 PRESS RELEASE

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Off...

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stock in a registered direct offering at a purchase price of $0.363 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class A warrants to purchase up to an aggregate of 5,640,958 shares of common stock and, unregiste...

 PRESS RELEASE

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that will participate in two upcoming investor conferences. Details for the presentations are as follows: Event: Date and Time: Tuesday, May 21, 2024, at 3:20 PM ET Event: Date and Time: Wednesday, May 22, 2024, at 3:40 PM ET Live webcasts of the presentations will be accessible on the page of the section of the Company’s website, . About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is a...

 PRESS RELEASE

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provid...

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch